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OBJECTIVES We studied angiographic outcome and its predictors after traditional coronary balloon
angioplasty in diabetics. We further examined whether changes in ejection fraction were
influenced by the status of the dilated site(s) at follow-up.
BACKGROUND Recent studies have suggested that diabetics have a particularly poor outcome after balloon
angioplasty. The reasons for this observation are not known.
METHODS We investigated procedural and six-month angiographic outcome, analyzed by quantitative
coronary angiography, and left ventricular function in 485 consecutive diabetics (627 lesions)
treated by balloon angioplasty without stent implantation.
RESULTS The procedure was successful in 455 (94%) patients; angiographic follow-up was available in
377 patients (83%). At follow-up, the rates of restenosis and total occlusion were 62% and
13%, respectively. Five independent predictors of restenosis were identified: the presence of
organ damage, a saphenous vein graft (SVG) angioplasty, a bifurcation lesion, a Thrombolysis
in Myocardial Infarction (TIMI) flow ,3 preprocedure and the degree of residual stenosis.
Four independent predictors of vessel occlusion were identified: treatment with insulin, a
SVG angioplasty, a TIMI flow ,3 preprocedure and the degree of residual stenosis after
angioplasty. Late vessel occlusion at angioplasty site(s) was observed in 15% of patients,
ranging from 11% for a one-site procedure to 37% for a three-site procedure. This
complication was associated with a decrease in ejection fraction at follow-up (26.2 6 9.9%,
p 5 0.0001), whereas no significant change was observed in patients without occlusion.
CONCLUSIONS This study shows that late vessel occlusion is a frequent mode of restenosis in diabetic patients
and is associated with a significant decrease in ejection fraction. This could partly explain the
poor long-term clinical outcome reported in such patients after traditional balloon angio-
plasty. (J Am Coll Cardiol 1999;34:476–85) © 1999 by the American College of Cardiology
Coronary artery disease is frequently encountered in diabetic
patients (1). Revascularization may be accomplished in such
patients either by coronary artery bypass grafting or by
percutaneous transluminal coronary angioplasty (PTCA).
Diabetes has previously been associated with high restenosis
rates after balloon angioplasty (2–6) and a poor long-term
clinical outcome (7–10). The results of these studies have
recently called into question the use of balloon angioplasty
in this subset of patients. However, the actual rate of
restenosis after balloon angioplasty in diabetics is still not
clearly known, varying from 35% to 71%, these figures being
drawn from studies that included only small numbers of
diabetic patients (3–6,11–17). It is still not clear whether
diabetics may be considered as a homogeneous population
regarding their angiographic outcome or whether some
additional risk factors may influence outcome. In addition
the BARI and CABRI studies (9,10), by showing that
clinical outcome of diabetic patients treated by balloon
angioplasty was worse than after bypass surgery, may sug-
gest a specific deleterious interaction between diabetes and
vascular healing after angioplasty. However, the link be-
tween angiographic and clinical outcome is not known.
We thus studied the procedural and six-month angio-
graphic outcome, assessed by quantitative coronary angiog-
raphy (QCA), in 485 consecutive diabetics (627 lesions)
who underwent traditional coronary balloon angioplasty
without adjunctive stent implantation in our institution,
where we recommend angiographic follow-up to all patients
who undergo a successful procedure. We further determined
the predictors of angiographic outcome in that population
and examined whether changes in left ventricular function
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between PTCA and follow-up were influenced by the status
of the dilated sites at follow-up angiography.
METHODS
Study population. From the records of our catheterization
laboratory, we identified 485 diabetics (358 men and 127
women) out of 2,670 (18%) patients treated by traditional
balloon angioplasty without adjunctive stent implantation
between January 1993 and December 1995. Patients under-
going primary or rescue balloon angioplasty for acute
myocardial infarction were not included.
At the time of the initial procedure patients were classi-
fied as diabetic if they were treated by oral hypoglycemic
drugs or insulin or if they had a previous history, docu-
mented on their medical chart, of elevated ($140 mg/dl)
fasting blood glucose on at least two separate occasions in
conjunction with ongoing dietary measures. They were
classified in three categories depending on antidiabetic
management at the time of the initial procedure: 1) diet
alone, 2) oral hypoglycemic drugs (diet and oral hypoglyce-
mic drugs but no insulin) and 3) insulin (irrespective of
other therapy).
Baseline blood glucose and creatinine levels as well as the
presence of other organ damage (retinopathy, nephropathy,
neuropathy), as documented in the medical charts, were
recorded.
Angioplasty procedure. Balloon angioplasty was per-
formed according to the standard technique in our labora-
tory (18). All patients received aspirin (100 to 300 mg/day)
started at least 24 h before the procedure and continued
indefinitely. A bolus dose of heparin (10,000 IU) was
administered just before PTCA. When the procedure was
performed in the morning, no heparin was administered
after the procedure, and the introducer sheath was removed
when the effects of heparin had worn off. When the
procedure was performed in the afternoon, 1,000 IU of
heparin per hour were infused until 6 AM the next day, and
the sheath was removed later that morning (18). A vascular
segment was considered successfully treated when the re-
sidual luminal narrowing in the dilated segment, immedi-
ately after angioplasty, was ,50%. The procedure was
considered successful when at least one vascular segment
was successfully treated and when no major complication
(electrocardiographic or enzymatic evidence of myocardial
infarction, the need for bypass surgery during hospitaliza-
tion or in-hospital death) occurred.
Angiography was performed in at least two projections,
after intracoronary injection of isosorbide dinitrate (2 mg)
and just before and immediately after angioplasty. These
projections were recorded in our database, and the
follow-up angiogram was performed after the intracoronary
injection of isosorbide dinitrate in the same projections.
Angiographic and clinical follow-up. During the study
period we routinely attempted to obtain a follow-up angio-
gram six months after successful angioplasty, regardless of
symptomatic status; angiography was performed earlier if
there was a clinical indication. Patients with a failed
procedure or patients who underwent surgical revasculariza-
tion without a new coronary angiogram within six months
or patients who died without a new coronary angiogram
within six months were considered noneligible for the
angiographic follow-up. Angiographic follow-up was actu-
ally performed at a mean of 6.9 6 2.7 months in 377
patients (84% of eligible patients) and 476 lesions. Clinical
follow-up was obtained at six months.
Angiographic analyses. The qualitative analyses were per-
formed independently by two experienced interventional
cardiologists. Disagreements were resolved by a further joint
reading. Lesions were classified in accordance with the
American Heart Association/American College of Cardiol-
ogy classification as modified by Ellis et al. (19). The
anterograde blood flow was graded using the classification
of the Thrombolysis in Myocardial Infarction (TIMI) study
group (20).
Quantitative computer-assisted angiographic measure-
ments were performed on end-diastolic frames with use of
the CAESAR (Computer-Assisted Evaluation of Stenosis
and Restenosis) system. A detailed description of this
system has been reported previously (21). We routinely
perform angiography in at least two projections after the
intracoronary injection of isosorbide dinitrate (2 mg). These
projections were recorded in our database, and the
follow-up angiogram was performed, after injection of
isosorbide dinitrate, in the same projections. The following
definitions were used: the acute gain associated with the
procedure was defined as the difference between the mini-
mal lumen diameter (MLD) immediately after the proce-
dure and the MLD before the procedure; the late loss
during the follow-up period was defined as the difference
between the MLD immediately after the procedure and the
MLD at follow-up; the net gain was defined as the
difference between the acute gain and the late loss; resten-
osis was defined as a .50% diameter stenosis at follow-up,
and finally, complete vessel occlusion was defined as a TIMI
grade flow 5 0 or 1.
Abbreviations and Acronyms
CI 5 confidence interval
LVEDVI 5 left ventricular end-diastolic volume index
LVEF 5 left ventricular ejection fraction
MLD 5 minimal lumen diameter
QCA 5 quantitative coronary angiography
PTCA 5 percutaneous transluminal coronary
angioplasty
SVG 5 saphenous vein graft
TIMI 5 Thrombolysis in Myocardial Infarction
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Quantitative evaluation of global left ventricular func-
tion. Ventricular function was evaluated on single-plane
right anterior oblique projection (30°) obtained before
angioplasty and at follow-up. The left ventricular contours
on end-systolic and end-diastolic frames were manually
traced by a single observer who was unaware of the study
protocol. The tracings were then digitized with a writing
tablet and light pen into a PC 486 microcomputer. The left
ventricular end-diastolic volume index (LVEDVI) (ml/m2)
and left ventricular ejection fraction (LVEF) (percent short-
ening) were calculated according to the area length method,
with use of the formula described by Kennedy et al. (22).
Statistical analysis. Data are presented as mean 6 SD. For
the univariate analysis, continuous variables were divided
into tertiles. Differences between proportions were assessed
by chi-square analysis. Comparisons between groups for
continuous data were made with paired Student t test or
analysis of variance followed by the Scheffe´ F test as
appropriate. A value of p , 0.05 was considered to indicate
statistical significance.
To study the relation between a binary outcome param-
eter and multiple categorical and continuous determinants,
a multiple logistic regression analysis was performed. Cat-
egorical independent variables were encoded as 0 (absent) or
1 (present). Continuous independent variables were incor-
porated without any change. The analysis was performed
using the logistic procedure of the SAS software (version
6.11, SAS Institute, Cary, North Carolina) with a stepwise
selection of the independent variables. Significance levels for
entry and removal were 0.05 in both cases.
RESULTS
Baseline characteristics. The baseline characteristics of
the study population are shown in Table 1. Most of the 485
diabetics were male (74%), with a mean age of 62 6 9 years.
Thirty-one percent had documented complication of diabe-
Table 1. Baseline Clinical Characteristics of the 485 Diabetic Patients According to Their Antidiabetic Management
All Patients Diet Alone
Oral
Hypoglycemic Drugs Insulin p
Number of patients 485 105 323 57
Age (yr) 62 6 9 63 6 10 62 6 9 58 6 10 0.003
Male 358 (74) 77 (73) 248 (77) 33 (58) 0.01
Smoking status
Never 188 (39) 32 (31) 125 (39) 31 (55)
Former 170 (35) 40 (38) 115 (35) 15 (26) 0.06
Current 127 (26) 33 (31) 83 (26) 11 (19)
Hypertension 316 (65) 74 (70) 203 (63) 39 (68) NS
Hypercholesterolemia
,250 mg/dl without treatment 176 (36) 28 (27) 125 (39) 23 (40)
,250 mg/dl with treatment 194 (40) 50 (47) 121 (37) 23 (40) NS
$250 mg/dl 115 (23) 27 (26) 77 (24) 11 (20)
Family history of CAD 196 (40) 56 (53) 118 (37) 22 (39) 0.01
Glucose (mmol/liter) 8.71 6 3.05 7.80 6 2.49 8.79 6 2.99 9.68 6 3.98 0.001
Creatinine (mmol/liter) 103.28 6 79.30 116.38 6 127.52 95.76 6 24.60 122.22 6 139.56 0.02
Organ damage
Retinopathy 54 (11) 6 (6) 25 (8) 23 (40) 0.0001
Nephropathy 100 (21) 26 (25) 57 (18) 17 (30) 0.06
Neuropathy 25 (5) 0 (0) 11 (3) 14 (25) 0.0001
At least one of the above 150 (31) 31 (30) 85 (26) 34 (59) 0.0001
Previous PTCA 184 (38) 38 (36) 123 (38) 23 (40) NS
Previous CABG 39 (8) 5 (5) 32 (10) 2 (4) NS
Stable angina 229 (47) 50 (48) 154 (48) 25 (44) NS
Unstable angina 116 (24) 25 (24) 80 (25) 11 (19) NS
Recent (,1 mo) MI 140 (29) 30 (29) 89 (28) 21 (37) NS
Anterior 72 16 47 9
Inferior 55 10 35 10 NS
Lateral 13 4 7 2
Number of diseased vessels 1.78 6 0.76 1.70 6 0.75 1.80 6 0.77 1.78 6 0.73 NS
Number of treated lesions 1.29 6 0.51 1.28 6 0.49 1.30 6 0.52 1.24 6 0.47 NS
LVEF (%) 58.6 6 14.8 59.9 6 14.5 58.8 6 14.6 54.8 6 15.7 NS
LVEDVI (ml/m2) 75.1 6 20.6 74.1 6 19.3 75.7 6 21.2 74.0 6 19.3 NS
Data are n (%) unless otherwise stated.
CABG 5 coronary artery bypass grafting; CAD 5 coronary artery disease; LVEDVI 5 left ventricular end-diastolic volume index; LVEF 5 left ventricular ejection fraction;
MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
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tes other than atherosclerosis (nephropathy, neuropathy or
retinopathy). Twenty-four percent of the patients had
unstable angina, and 29% had experienced a recent (,1
month) myocardial infarction. The numbers of diseased
vessels and treated lesions were 1.78 6 0.76 and 1.29 6
0.51, respectively.
Twenty-two percent of patients were treated with diet
alone, 66% were treated with oral hypoglycemic drugs and
12% with insulin. Patients treated with insulin were
younger, more often women, smoked less and had more
frequently documented complications of diabetes than the
two other subgroups. Clinical presentation and severity of
coronary artery disease was similar among the three sub-
groups.
The baseline lesion characteristics are shown in Table 2.
Balloon angioplasty was performed at a recent infarct-
related lesion in 21% of cases and for restenosis in 22% of
cases. The dilated lesion was most often (47%) located in
the left anterior descending artery, and less frequently in the
right coronary artery (27%), the left circumflex artery (23%)
or a saphenous vein graft (SVG) (4%). Eighteen percent of
the lesions had TIMI grade flow ,3.
Immediate outcome. Procedural success was obtained in
455 patients (94%, Table 3). There were 15 major in-
hospital complications: three patients had nonfatal myocar-
dial infarction, four had re-PTCA, two had emergent
coronary bypass grafting and six died during hospitalization.
Uncomplicated failure (residual stenosis $50% by QCA)
occurred in 15 additional patients. No significant difference
was observed among the patients when classified according
to their antidiabetic regimen.
Six-month angiographic outcome. Five patients died and
two had coronary bypass surgery after discharge without
recurrent angiography. Three hundred seventy-seven of the
448 remaining patients (84%) underwent angiographic
follow-up. No significant difference in angiographic out-
Table 2. Baseline Lesion Characteristics
Number of Lesions
Total 627
Infarct (,1 mo) related lesion 133 (21)
Previous PTCA at same site 138 (22)
Site of angioplasty
LAD 295 (47)
RCA 162 (26)
LCx 147 (23)
SVG 23 (4)
ACC/AHA
A 188 (30)
B1 194 (31)
B2 180 (29)
C 65 (10)
Calcification 100 (21)
Eccentric lesion 246 (39)
Ulceration 71 (11)
Bifurcation 85 (14)
Angulated lesion 38 (6)
Thrombus 70 (11)
Lesion length (mm) 8.5 6 3.8
TIMI grade flow
0 37 (6)
1 29 (5)
2 49 (8)
3 512 (82)
Data are n (%) unless otherwise stated.
ACC/AHA 5 American College of Cardiology/American Heart Association;
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary
artery; PTCA 5 percutaneous transluminal coronary angioplasty; RCA 5 right
coronary artery; SVG 5 saphenous vein graft; TIMI 5 Thrombolysis in Myocardial
Infarction.
Table 3. Procedural Outcome of the 485 Diabetic Patients According to Their Antidiabetic Management
All
Patients
Diet
Alone
Oral Hypoglycemic
Drugs Insulin p
Number of patients 485 105 323 57
1-site dilation 355 (73) 78 (74) 234 (72) 43 (75)
2-site dilation 118 (24) 25 (24) 80 (25) 13 (23) NS
3-site dilation 12 (3) 2 (2) 9 (3) 1 (2)
Procedural success 455 (94) 101 (96) 303 (94) 51 (89) NS
Uncomplicated failure (residual stenosis $50%) 15 (3) 2 (2) 10 (3) 3 (5) NS
Complicated failure 15 (3) 2 (2) 10 (3) 3 (5) NS
Myocardial infarction 3 0 3 0
In-hospital re-PTCA 4 0 3 1
In-hospital CABG 2 2 0 0
Death 6 0 4 2
Death after discharge 5 (1) 1 (,1) 3 (,1) 1 (,1) NS
CABG after discharge 2 (,1) 0 (0) 1 (,1) 1 (,1) NS
Patients eligible for angiographic follow-up 448 (98)* 98 (97)* 302 (99)* 48 (94)* NS
Patients with angiographic follow-up 377 (84)† 80 (82)† 257 (85)† 40 (83)† NS
*Percentage of patients with procedural success. †Percentage of patients eligible for angiographic follow-up. Data are n (% of all patients) unless otherwise stated.
CABG 5 coronary artery bypass grafting; PTCA 5 percutaneous transluminal coronary angioplasty.
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come was observed among the patients when classified
according to their antidiabetic regimen.
The 71 patients without angiographic follow-up were
slightly older than the 377 patients with angiographic
follow-up (65 6 9 years vs. 61 6 9 years, p , 0.05), with
a higher proportion of patients with hypertension (76% vs.
63%, p , 0.05) and a lower proportion of patients with
hypercholesterolemia (51% vs. 67%, p , 0.05). No differ-
ence was observed between patients with or without
follow-up in the other major baseline characteristics de-
scribed in Tables 1 and 2.
Table 4 summarizes the quantitative angiographic data in
the 476 lesions with angiographic follow-up. Restenosis,
defined as the presence of .50% stenosis in the dilated
segment at follow-up, was present in 297 (62%) of the 476
lesions. Of these lesions, 60 (13% of the 476 lesions) were
totally occluded at follow-up and 237 (49% of the 476
lesions) had nonocclusive restenosis. Target lesion revascu-
larization was performed at 165 lesions (35% of the 476
lesions).
Two hundred fifty-six of the 377 patients (68%) had at
least one lesion with restenosis at follow-up. Of these
patients, 55 (15% of the 377 patients) had at least one
dilated lesion occluded at follow-up. For a patient, the risk
that $1 lesion would be occluded at follow-up increased
with the number of sites dilated during the initial procedure:
11% for a one-site procedure, 25% for a two-site procedure
and 37% for a three-site procedure (p 5 0.002). The risk of
occlusion at a lesion was not modified by the number of
lesions treated during the procedure (p 5 NS). At follow-
up, 20 patients with late vessel occlusion had no angina
(36%), 18 had stable angina (33%) and 17 had unstable
angina or clinical evidence of recent myocardial infarction
(31%).
Predictors of restenosis. We analyzed predictors of resten-
osis in the 476 lesions with angiographic follow-up. All
baseline characteristics as described in Tables 1 and 2, as
well as the results of QCA performed before and immedi-
ately after the procedure were included in the analysis. Table
5 shows the univariate predictors of restenosis (.50%
diameter stenosis at follow-up) in the 476 lesions with
angiographic follow-up. Among the clinical parameters, the
level of creatinine and the presence of organ damage were
associated with a higher rate of restenosis. Among the
lesion-related parameters, angioplasty at a de novo rather
than a restenotic lesion, a SVG lesion, a complex lesion, an
eccentric lesion, a lesion containing thrombus, a long lesion,
a lesion with a TIMI grade flow ,3 preprocedure, smaller
MLD or a higher percent stenosis before PTCA as well as
smaller MLD or a higher percent stenosis after PTCA were
univariate predictors of restenosis.
By multivariate analysis, five independent predictors of
restenosis were identified: the presence of organ damage,
angioplasty at a SVG, a bifurcation lesion, a lesion with
TIMI grade flow ,3 preprocedure and the degree of
residual stenosis after angioplasty (Table 6).
Predictors of late vessel occlusion. Table 7 shows the
univariate predictors of late vessel occlusion. Among the
clinical parameters, the requirement for insulin therapy and
the presence of unstable angina or recent myocardial infarc-
tion were associated with a higher rate of late vessel
occlusion. Among the lesion-related parameters, angio-
plasty at an infarct-related lesion, a SVG, a complex lesion,
a lesion containing thrombus, a long lesion, a lesion with a
TIMI grade flow ,3 preprocedure as well as smaller MLD
or a higher percent stenosis before PTCA were univariate
predictors of late vessel occlusion.
By multivariate analysis, four independent predictors of
late vessel occlusion were identified: requirement for insulin
therapy, angioplasty at a SVG, a lesion with TIMI grade
flow ,3 preprocedure and the degree of residual stenosis
after angioplasty (Table 8).
Changes in left ventricular function. Among the 377
patients with angiographic follow-up, 344 (91%) had ven-
triculograms before PTCA and at follow-up that were
suitable for determination of left ventricular function. In the
group as a whole, there was a small but statistically signif-
icant (p 5 0.01) decrease in LVEF from 59.1 6 15.0%
Table 4. Quantitative Angiography in the 476 Lesions With
Angiographic Follow-up
Number of
Lesions
Total 476
Reference diameter (mm)
Before 2.96 6 0.55
After 2.97 6 0.54
Follow-up 2.94 6 0.55
Minimal lumen diameter (mm)
Before 0.76 6 0.39
After 1.93 6 0.48
Follow-up 1.19 6 0.72
Diameter stenosis (%)
Before 74 6 13
After 33 6 11
Follow-up 59 6 23
Acute gain (mm) 1.17 6 0.55
Late loss (mm) 0.74 6 0.73
Net gain (mm) 0.43 6 0.71
Restenosis at follow-up
Total occlusion, n (%) [*] 60 (13) [10–16]
Diameter stenosis .50% without total
occlusion, n (%) [*]
237 (49) [45–53]
Diameter stenosis .50%, n (%) [*] 297 (62) [58–66]
Target lesion revascularization
re-PTCA (n) 152
CABG (n) 13
Total, n (%) [*] 165 (35) [31–39]
*95% confidence intervals. Data are mean 6 SD unless otherwise stated.
CABG 5 coronary artery bypass grafting; PTCA 5 percutaneous transluminal
coronary angioplasty.
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before the PTCA to 57.9 6 15.1% at follow-up. The
LVEDVI at follow-up (74.1 6 21.8 ml/m2) was similar to
the LVEDVI before PTCA (74.7 6 21.4 ml/m2). Patients
were classified into three subgroups based on the patency of
the dilated sites at follow-up: 1) patients with (at least one)
occlusion at follow-up, 2) patients without occlusion but
with (at least one) restenosis and 3) patients without
occlusion or restenosis. There were no differences in LVEF
and LVEDVI among subgroups before PTCA. During the
follow-up period, however, there was a decrease in LVEF in
patients with occlusion at follow-up (26.2 6 9.9%, p 5
0.0001), whereas no significant change was observed in the
two other subgroups (10.5 6 9.9% and 21.5 6 9.5%, p 5
NS). Similarly a trend for an increase in LVEDVI was also
noted in patients with vessel occlusion (12.6 6 10.2 ml/m2,
p 5 0.06), whereas no change was observed in the two other
groups (20.8 6 11.3 ml/m2 and 21.7 6 12.1 ml/m2, p 5
NS). These changes resulted in a significantly (p 5 0.0005)
lower LVEF in the group of patients with occlusion at
follow-up (50.8 6 12.4%) compared with the two other
groups without occlusion (59.1 6 15.2% and 59.6 6
15.2%). Left ventricular end-diastolic volume index at
follow-up was not statistically different among the three
groups.
DISCUSSION
This study confirms that in diabetic patients, balloon
angioplasty without stent implantation is associated with a
poor angiographic outcome. More importantly, by virtue of
the large number of patients included and the objective
assessment of the results of angioplasty by QCA, it extends
the results of previous studies by providing a more accurate
estimate of the rate of restenosis in diabetics (62%). This
study shows in addition that late vessel occlusion, 13% of
lesions and 15% of patients, is a frequent mode of restenosis
in diabetics and that this specific complication has a notable
Table 5. Univariate Predictors of Restenosis in the 476 Lesions
With Follow-up
Restenosis
(%) p
Creatinine (mmol/liter)
,84 (n 5 140) 55
84# ,102 (n 5 185) 63 0.05
$102 (n 5 151) 69
Organ damage
Yes (n 5 117) 72 0.01
No (n 5 359) 59
Nephropathy
Yes (n 5 78) 74 0.01
No (n 5 398) 60
Clinical status
Stable angina (n 5 247) 57
Unstable angina (n 5 116) 69 0.06
Recent (,1 mo) MI (n 5 113) 66
Infarct (,1 mo) MI-related lesion
Yes (n 5 99) 70 0.09
No (n 5 377) 60
Previous PTCA at same site
Yes (n 5 109) 51 0.01
No (n 5 367) 66
Site of angioplasty
LAD (n 5 243) 65
RCA (n 5 118) 58 0.005
LCx (n 5 97) 55
SVG (n 5 18) 94
ACC/AHA
A (n 5 157) 50
B1 (n 5 141) 58 0.0009
B2 (n 5 134) 70
C (n 5 44) 75
Eccentric lesion
Yes (n 5 184) 68 0.04
No (n 5 292) 59
Bifurcation
Yes (n 5 71) 72 0.07
No (n 5 405) 61
Thrombus
Yes (n 5 51) 76 0.02
No (n 5 425) 61
Lesion length (mm)
,7 (n 5 131) 54
7# ,9 (n 5 197) 61 0.01
$9 (n 5 148) 71
TIMI grade
,3 (n 5 76) 82 0.0002
3 (n 5 400) 59
Quantitative coronary angiography
Reference diameter (mm)
,2.70 (n 5 151) 68
2.70# ,3.15 (n 5 172) 56 0.09
$3.15 (n 5 153) 64
MLD before PTCA (mm)
,0.60 (n 5 159) 69
0.60# ,0.95 (n 5 170) 62 0.03
$0.95 (n 5 147) 55
(continued)
Table 5. Continued.
Restenosis
(%) p
Stenosis before PTCA (%)
,68 (n 5 159) 55
68# ,80 (n 5 168) 63 0.03
$80 (n 5 149) 70
MLD after PTCA (mm)
,1.70 (n 5 156) 69
1.70# ,2.05 (n 5 156) 62 0.05
$2.05 (n 5 164) 56
Stenosis after PTCA (%)
,28 (n 5 153) 59
28# ,38 (n 5 164) 58 0.03
$38 (n 5 159) 70
MI 5 myocardial infarction; MLD 5 minimal lumen diameter. Other abbreviations
as in Table 2.
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deleterious effect on left ventricular function. Finally, pre-
dictors of late vessel occlusion and restenosis were identi-
fied. These findings, especially the high rate of late vessel
occlusion, could explain the poor long-term clinical out-
come previously reported in diabetic patients after balloon
angioplasty.
Procedural outcome. The overall results of the angioplasty
procedure were satisfactory, with a 94% procedural success
rate. This is in agreement with a previous study by Stein et
al. (8), including over 10,000 patients, in which the proce-
dural success rate was similar in diabetic and nondiabetic
patients (87% vs. 88%) and with the results of the BARI and
EPILOG studies (9,23), in which in-hospital outcome after
PTCA did not differ between diabetics and nondiabetics.
Restenosis rates in diabetic patients after balloon angio-
plasty. Several studies have suggested that diabetes was a
risk factor for restenosis after balloon angioplasty (2–6,12–
17,24,25) (Table 9). In those studies the restenosis rate
ranged from 35% to 71%. Each of these studies, however,
had at least one of the following limitations; small numbers
of diabetics (n , 100) (3,5,6,13–17,24,25), low rates of
angiographic follow-up (,70%) (4,6,12,13,15,16,24) or
assessment of the degree of stenosis without QCA (3–6,12–
14,16). The present study has none of these limitations and
may provide a more accurate estimate of the restenosis rate
(62%, 95% confidence interval [CI]: 58% to 66%). This rate
is significantly higher than that usually reported in the
general population (30% to 35%) (2,26,27) and the resten-
osis rate we previously reported in a consecutive series of
243 nondiabetic patients treated in our institution with the
same technique during the same time frame (36%, 95% CI:
30% to 42%) (25).
Mechanisms of lesion recurrence after balloon angio-
plasty in diabetics. Our study also demonstrates that late
vessel occlusion, which occurs in 13% (95% CI: 10% to
16%) of all treated lesions and in 15% of patients (95% CI:
11% to 19%), is a frequent mode of restenosis in that
population; nonocclusive restenosis is observed in 49% (95%
CI: 45% to 53%) of lesions. The rate of late vessel occlusion
in the present study (13%) is higher than that observed in
the general population (3% to 6%) (2,26–28) and higher
than the rate we previously reported in a contemporary
series of 243 nondiabetic patients treated with the same
technique (3%, 95% CI: 1% to 5%) (25). This rate compares
with the high rates of late vessel occlusion that are found in
patients undergoing angioplasty for total occlusion (19%)
Table 6. Multiple Logistic Regression Analysis for the Dependent Variable of Restenosis
Independent Variable
Beta
Coefficient SE
p
Value
Odds
Ratio 95% CI
TIMI ,3 before angioplasty 1.16 0.32 0.0003 3.18 1.70–5.95
% stenosis after angioplasty 0.03 0.01 0.004 1.03 1.01–1.05
Saphenous vein graft 2.81 1.06 0.008 16.55 2.09–131.65
Organ damage 0.52 0.24 0.03 1.68 1.05–2.69
Bifurcation lesion 0.58 0.29 0.04 1.79 1.01–3.17
CI 5 confidence interval; SE 5 standard error; TIMI 5 Thrombolysis in Myocardial Infarction.
Table 7. Univariate Predictors of Late Vessel Occlusion in the
476 Lesions With Follow-up
Occlusion (%) p
Insulin therapy
Yes (n 5 50) 23 0.02
No (n 5 426) 12
Clinical status
Stable angina (n 5 247) 9
Unstable angina (n 5 116) 15 0.02
Recent (,1 mo) MI (n 5 113) 19
Infarct (,1 mo) related lesion
Yes (n 5 99) 20 0.01
No (n 5 377) 11
Site of angioplasty
LAD (n 5 243) 10
RCA (n 5 118) 14 0.001
LCx (n 5 97) 9
SVG (n 5 18) 50
ACC/AHA
A (n 5 157) 8
B1 (n 5 141) 15 0.04
B2 (n 5 134) 13
C (n 5 44) 23
Thrombus
Yes (n 5 51) 35 0.0001
No (n 5 425) 10
Lesion length
,7 (n 5 131) 8
7# ,9 (n 5 197) 12 0.04
$9 (n 5 148) 18
TIMI grade flow
,3 (n 5 76) 36 0.0001
3 (n 5 400) 8
Quantitative coronary angiography
MLD before PTCA (mm)
,0.60 (n 5 159) 20
0.60# ,0.95 (n 5 170) 10 0.001
$0.95 (n 5 147) 7
Stenosis before PTCA (%)
,68 (n 5 159) 9
68# ,80 (n 5 168) 9 0.001
$80 (n 5 149) 21
Abbreviations as in Table 5.
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(27) or for angioplasty after myocardial infarction (13% to
21%) (29,30). A critical role for late vessel occlusion after
balloon angioplasty in diabetics was already suggested by
one of our previous studies (25) and Rensing et al.’s (2)
report. These results therefore suggest that two distinct
phenomena are involved in lesion recurrence after balloon
angioplasty in diabetic patients: nonocclusive restenosis and
late vessel occlusion.
The prothrombotic milieu present in diabetic patients is
likely to explain the increased rate of late vessel occlusion
observed in that population (31,32). Previous studies dem-
onstrating that thrombus is both more frequently associated
with coronary lesions in diabetics (33) and a predictor of late
vessel occlusion after angioplasty (34) are consistent with
this suggestion.
The respective roles of intimal hyperplasia and vascular
remodeling in non-occlusive restenosis after balloon angio-
plasty in diabetics are not known. Kornowski et al.’s (35)
study using intravascular ultrasound, suggests that intimal
tissue growth is increased in diabetic patients after angio-
plasty; Moreno et al.’s (36) preliminary report suggests that
the specific feature of atherectomy specimens from rest-
enotic lesions retrieved in diabetics is not an enhanced
smooth muscle proliferation but rather a greater fibrotic
response that may lead to vessel constriction.
Risk factors for lesion recurrence after balloon angio-
plasty in diabetic patients. To the best of our knowledge
there is no information on risk factors of six-month angio-
graphic outcome in the diabetic population. Most of the
parameters we identified as risk factors for restenosis or late
vessel occlusion are not specific to the diabetic population
and were previously described in unselected populations
(degree of baseline stenosis, unstable angina, totally oc-
cluded lesions and visible thrombus) (2). Similarly angio-
plasty at SVGs or recent infarct-related lesions were previ-
ously shown to be associated with high rates of restenosis or
occlusion at follow-up (29,37,38).
Four points deserve specific comment. First, some risk
factors identified were associated with unacceptable risks of
occlusion (20% to 50%) and restenosis (70% to 94%)
(angiographically visible thrombus, TIMI grade flow ,3,
infarct-related lesions or SVG). Second, even in the absence
of known risk factors such as angioplasty at infarct-related
lesions or at SVGs the risks of late vessel occlusion or
restenosis in diabetics (11% and 60%, respectively) were still
higher than those observed in the general population (2,26–
Table 8. Multiple Logistic Regression Analysis for the Dependent Variable of Late
Vessel Occlusion
Independent Variable
Beta
Coefficient SE
p
Value
Odds
Ratio 95% CI
Insulin 0.87 0.59 0.03 2.39 1.06–5.40
Saphenous vein graft 2.91 0.63 0.0001 18.42 5.37–63.18
TIMI ,3 before angioplasty 1.87 0.32 0.0001 6.46 3.46–12.07
% stenosis after angioplasty 0.03 0.01 0.03 1.03 1.01–1.06
CI 5 confidence interval; SE 5 standard error; TIMI 5 Thrombolysis in Myocardial Infarction.
Table 9. Results of Prior Studies on Angiographic Outcome in Diabetic Patients
Author Year
Rate of
Angiographic
Follow-up
Diabetics at
Follow-up (n)
Method of
Analysis
Restenosis
Rate*
Holmes et al. (3) 1984 84% 43 Visual 47%
Vandormael et al. (12) 1987 62% NA Calipers 71%
Lambert et al. (6) 1988 57% 13 Visual 69%
Quigley et al. (5) 1989 88% 18 Visual 61%
Ellis et al. (13) 1989 62% 18 Calipers 61%
Macdonald et al. (14) 1990 71% 60 Calipers 41%
Bourassa et al. (15) 1991 65% 17 QCA 35%
Weintraub et al. (4) 1993 44% 322 Calipers 53%
Rabbani et al. (16) 1994 88% 13 Calipers 69%
Le Feuvre et al. (24) 1994 92% 21 QCA 66%
Van Belle et al. (25) 1997 83% 57 QCA 63%
Levine et al. (17) 1997 90% 96 QCA 56%
Present study 1998 84% 377 QCA 62%
*Restenosis rate was defined on a per lesion basis.
Calipers indicates electronic caliper assessment of restenosis; visual indicates visual assessment. NA 5 not available; QCA 5
coronary quantitative angiography.
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28). Third, diabetics treated with insulin had higher rates of
late vessel occlusion (23%) than patients treated with oral
hypoglycemic drugs or hypoglycemic diet (12%). The reason
for this observation is unclear, but may relate to an increased
production of plasminogen activator inhibitor-1 in the
vessel wall resulting in impaired local fibrinolysis (32). This
observation is consistent with previous reports, in which
insulin-requiring diabetics had a worse late clinical outcome
after angioplasty than non–insulin-requiring diabetics
(8,39). Finally, because advanced glycosylation is considered
as the common mechanism implicated in the initiation and
acceleration of multiple organ damage (nephropathy, neu-
ropathy, retinopathy) (40), the increased rate of restenosis
observed in the presence of organ damage may support a
role of advanced protein glycosylation in the restenotic
process in diabetics (31).
Occlusive restenosis and midterm outcome. The propen-
sity of diabetic patients to develop ischemia without, or with
only limited symptoms is well known (41,42). In the present
study, 36% of late vessel occlusions were asymptomatic.
However, vessel occlusion was associated with a significant
decrease in ejection fraction (26.0%). Furthermore, due to
the large proportion of patients with such occlusion (15%),
a significant decrease in ejection fraction (21.3%) was
detected in the population as a whole. Vessel occlusion was
also associated with a trend for an increase in left ventricular
diastolic volumes. Nonocclusive restenosis, on the other
hand, had no effect on left ventricular function. This
observation underlines the shortcoming of clinical follow-up
in detecting late vessel occlusion. The threshold for the
performance of follow-up angiography should perhaps be
more liberal in this population.
These results may also provide some insights into some of
the findings of the BARI study (9). By showing that 5-year
survival of diabetic patients with two- or three-vessel disease
treated by balloon angioplasty was worse than after bypass
surgery, the BARI study suggested a specific interaction
between diabetes, vascular healing after angioplasty and
survival. The 25% occlusion rate per diabetic patient treated
at two or more sites, as reported in the present study,
combined with the effect of these occlusions on left ventric-
ular function may constitute an attractive explanation for the
BARI findings.
Study limitations. This was a retrospective single-center
study; thus, complete information on the degree of diabetic
control was not available and the technique of PTCA and
medical management at our institution may have influenced
the results. However, the patients were a consecutive group
that underwent the angioplasty procedure in an institution
where the probability that a patient undergoes follow-up
angiography is less dependent on the symptomatic status
after angioplasty. The high rate of angiographic follow-up
coupled with the use of quantitative coronary angiography
to assess angiographic outcome in a large cohort of patients,
allowed an objective assessment of the angiographic prob-
ability of restenosis and late vessel occlusion. Finally this
study is focused on the six-month follow-up and does not
provide information on late clinical outcome.
Clinical implications. This study demonstrates that de-
spite a satisfactory procedural outcome, traditional balloon
angioplasty in diabetics is associated with prohibitive rates
of angiographic restenosis and target lesion revasculariza-
tion. Furthermore, late vessel occlusion is a frequent mode
of restenosis and is associated with a negative effect on left
ventricular function. This emphasizes the need for new
strategies designed to prevent late vessel occlusion in this
setting. The results of recent studies suggest that the use of
glycoprotein IIb/IIIa blockade or intracoronary stents might
be useful to achieve this goal. In the EPILOG study,
subgroup analysis demonstrated that the combination of
glycoprotein IIb/IIIa blockade and balloon angioplasty was
associated with a reduction in ischemic events (death and
myocardial infarction) at six months in diabetic patients
(23). Similarly, we previously reported that intracoronary
stent implantation was associated with acceptable rates of
restenosis and late vessel occlusion (,30% and ,5%,
respectively) in a series of diabetic patients (n 5 88) treated
in our institution in a period contemporary to the present
study (25,43). Some of the risk factors identified in the
present study (thrombus, TIMI grade flow ,3 before
procedure, SVG, degree of residual stenosis) are consistent
with a possible benefit of these two strategies. These
observations should encourage prospective studies to evalu-
ate strategies designed to prevent late vessel occlusion. Our
results suggest also that, due to its negative impact on left
ventricular function, the high rate of occlusive restenosis
may partly explain the poor late clinical outcome previously
reported in this population (7–10). Whether a therapeutic
strategy leading to a decrease of late vessel occlusion after
angioplasty in diabetics improves late cardiac survival will
also require prospective investigation.
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